Company / Working Capital
Theravance Biopharma, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$380.2M
FY2025
5-year range
$108.8M / $380.2M
FY2021-FY2025
Trend
+194.7%
vs FY2024
Sector context
#115 of 213
Health Care
What the data says
At $380M, Theravance Biopharma, Inc.'s working capital ranks #115 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $109M in FY2023 to $479M in FY2016.
Based on SEC 10-K filings.
$380M in FY2025 with a 5-year CAGR of +7.1%.
Improved from $109M to $380M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +5.4%
- 5-Year CAGR
- +7.1%
- 10-Year CAGR
- -
Sector benchmark
#115 of 213 in Health CareTop 54% of 213This company $380.2M Sector average $934.6M
▼
-59.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.1%, indicating consistent growth.
- In FY2025, working capital increased 194.7% year-over-year.
- Ranks #115 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $380.2M | +194.7% |
| FY2024 | $129.0M | +18.6% |
| FY2023 | $108.8M | -66.5% |
| FY2022 | $324.7M | +69.8% |
| FY2021 | $191.3M | -29.1% |
| FY2020 | $269.8M | +19.0% |
| FY2019 | $226.8M | -47.8% |
| FY2018 | $434.3M | +37.3% |
| FY2017 | $316.2M | -34.0% |
| FY2016 | $479.2M | +154.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026